High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors
- PMID: 21212410
- DOI: 10.1158/0008-5472.CAN-10-3018
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors
Abstract
Proteasome inhibitors such as bortezomib exhibit clinical efficacy in multiple myeloma, but studies in acute myeloid leukemia (AML) have been disappointing to date. The apparent failure in AML likely reflects a lack of biological understanding that might clarify applications of proteosome inhibitors in this disease. Here we show that AML cells are considerably less sensitive than control noncancerous cells to bortezomib-induced cytotoxicity, permitting most bortezomib-treated AML cells to survive treatment. We traced reduced bortezomib sensitivity to increased basal levels of nuclear Nrf2, a transcription factor that stimulates protective antioxidant enzymes. Bortezomib stimulates cytotoxicity through accumulation of reactive oxygen species (ROS) but elevated basal levels of nuclear Nrf2 present in AML cells reduced ROS levels, permitting AML cells to survive drug treatment. We further found that the Nrf2 transcriptional repressor Bach1 is rapidly inactivated by bortezomib, allowing rapid induction of Nrf2-regulated cytoprotective and detoxification genes that protect AML cells from bortezomib-induced apoptosis. By contrast, nonmalignant control cells lacked constitutive activation of Nrf2, such that bortezomib-mediated inactivation of Bach1 led to a delay in induction of Nrf2-regulated genes, effectively preventing the manifestation of apoptotic protection that is seen in AML cells. Together, our findings argue that AML might be rendered sensitive to proteasome inhibitors by cotreatment with either an Nrf2-inhibitory or Bach1-inhibitory treatment, rationalizing a _targeted therapy against AML.
©2011 AACR.
Similar articles
-
Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.Hemoglobin. 2014;38(3):188-95. doi: 10.3109/03630269.2014.898651. Epub 2014 Mar 26. Hemoglobin. 2014. PMID: 24670032 Clinical Trial.
-
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.PLoS One. 2013 Aug 2;8(8):e69126. doi: 10.1371/journal.pone.0069126. Print 2013. PLoS One. 2013. PMID: 23936317 Free PMC article.
-
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.Haematologica. 2008 Jan;93(1):57-66. doi: 10.3324/haematol.11666. Haematologica. 2008. PMID: 18166786
-
Inhibiting BTB domain and CNC homolog 1 (Bach1) as an alternative to increase Nrf2 activation in chronic diseases.Biochim Biophys Acta Gen Subj. 2022 Jun;1866(6):130129. doi: 10.1016/j.bbagen.2022.130129. Epub 2022 Mar 12. Biochim Biophys Acta Gen Subj. 2022. PMID: 35292311 Review.
-
Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic _target.Onco_target. 2015 Mar 20;6(8):5490-500. doi: 10.18632/onco_target.3545. Onco_target. 2015. PMID: 25823927 Free PMC article. Review.
Cited by
-
Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1.Onco_target. 2011 Sep;2(9):658-68. doi: 10.18632/onco_target.321. Onco_target. 2011. PMID: 21911919 Free PMC article.
-
Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.Redox Biol. 2016 Aug;8:175-85. doi: 10.1016/j.redox.2016.01.007. Epub 2016 Jan 11. Redox Biol. 2016. PMID: 26795735 Free PMC article.
-
_targeting critical pathways in ferroptosis and enhancing antitumor therapy of Platinum drugs for colorectal cancer.Sci Prog. 2023 Jan-Mar;106(1):368504221147173. doi: 10.1177/00368504221147173. Sci Prog. 2023. PMID: 36718538 Free PMC article. Review.
-
The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies.Antioxidants (Basel). 2020 Nov 19;9(11):1151. doi: 10.3390/antiox9111151. Antioxidants (Basel). 2020. PMID: 33228209 Free PMC article. Review.
-
Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.Antioxid Redox Signal. 2013 Apr 10;18(11):1349-83. doi: 10.1089/ars.2011.4258. Epub 2012 Sep 28. Antioxid Redox Signal. 2013. PMID: 22900756 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous